The
Intellectual Property Owners Association (IPO) will offer a one-hour webinar
entitled: "Bio-Similars: The New Litigation Landscape" on Thursday,
April 22, 2010 beginning at 2:00 PM (EST). The IPO webinar will provide an overview of the healthcare
reform measure that creates a regulatory pathway for generic versions of
large-molecule biotech drugs, which bears some resemblance to the longstanding
Hatch-Waxman regime that sets out how generic drug companies can challenge patents
held by pharmaceutical companies on small-molecule medicines. The webinar will also examine the
differences between the two schemes, which are profound and will prove to be of
great importance in the years ahead.
The speakers include Stuart Watt of Amgen Inc. and F. Dominic Cerrito of
Jones Day. The registration fee
for the webinar is $100. Those
interested in registering for the webinar, can do so here.

Patent Law Weblog
recent posts
- Why the Alice Test is Stupid, Part IV: The Usefulness Paradox
- Teva Capitulates to Federal Trade Commission Coercion
- USPTO Issues Memoranda on Subject Matter Eligibility
- USPTO Revokes Guidance on AI-Assisted Inventorship, But Rules Remain Basically the Same
- Why the Alice Test is Stupid, Part III: Eligible Independent Claims Can Have Ineligible Dependent Claims
about
Posted in Conferences & CLE’s
One response to “Biosimilars CLE”
-
Biosimilars Seminar – Earn CLE
As promoted on the Patent Doc blog, an online webinar will be offered on April 22nd at 2 pm EST entitled “Biosimilars: The New Litigation Landscape”. The program is sponosored by the Intellectual Property Owners Association (IPO) and will feature speak…
LikeLike
Leave a reply to The Big Red Biotech Blog Cancel reply